Predicting ROS1 Fusions and Targetable Mutations in Non-small Cell Lung Cancer through H-score Pathological Analysis

被引：0
|
作者：
Soussi, G. [1 ,2 ]
Hercent, A. [3 ]
Gounant, V. [1 ,2 ]
Lupo, A. [4 ]
Cazes, A. [5 ]
Lamoril, J. [3 ]
Guyard, A. [5 ]
Theou-Anton, N. [3 ]
机构：
[1] Univ Paris Cite, Thorac Oncol Dept, Paris, France
[2] Nord Univ Paris Cite, Bichat Claude Bernard Univ Hosp, Canc Inst AP HP, CIC1425 CLIP2 Early Phase Canc Clin Trials Unit, Paris, France
[3] Univ Paris Cite, Canc Inst APHP Nord, Bichat Claude Bernard Univ Hosp, Dept Genet, Paris, France
[4] Univ Paris Cite, Cochin Univ Hosp, Dept Pathol, Paris, France
[5] Nord Univ Paris Cite, Bichat Claude Bernard Univ Hosp, Canc Inst AP HP, Dept Pathol, Paris, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Non-small cell lung cancer; ROS1; fusions; Immunohistochemistry;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP06.03-15
引用
收藏
页码：S489 / S489
页数：1
相关论文
共 50 条
  • [31] Cognitive Impact of Lorlatinib Administration in Advanced Non Small Cell Lung Cancer with ALK and ROS1 Fusions
    Tanzilli, A.
    Tosetto, L.
    Landi, L.
    Villani, V.
    Di Noia, V.
    Fusco, F.
    Pace, A.
    Stati, V.
    Cappuzzo, F.
    Cecere, F.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S641 - S641
  • [32] ROS1 FUSION GENES: POTENTIAL DRUG TARGETS IN NON-SMALL CELL LUNG CANCER
    Davies, Kurtis D.
    Le, Anh T.
    Theodoro, Mariana F.
    Skokan, Margaret C.
    Aisner, Dara L.
    Terracciano, Luigi M.
    Incarbone, Matteo
    Roncalli, Massimo
    Cappuzzo, Federico
    Camidge, Ross D.
    Doebele, Robert C.
    Garcia, Marileila V.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S146 - S146
  • [33] ROS1 gene rearrangement and copy number gain in non-small cell lung cancer
    Jin, Yan
    Sun, Ping-Li
    Kim, Hyojin
    Park, Eunhyang
    Shim, Hyo Sup
    Jheon, Sanghoon
    Kim, Kwhanmien
    Lee, Choon-Taek
    Chung, Jin-Haeng
    VIRCHOWS ARCHIV, 2015, 466 (01) : 45 - 52
  • [34] Analysis of Clinicopathological Features and Clinical Efficacy of Crizotinib in ROS1 Positive Non-Small Cell Lung Cancer
    Zhu, Y.
    Li, X.
    Wu, L.
    Chen, H.
    Wang, W.
    Xu, C.
    Fang, M.
    Shen, J.
    Du, K.
    Zhuang, W.
    Chen, Y.
    Chen, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S508 - S508
  • [35] ROS1 gene rearrangement and copy number gain in non-small cell lung cancer
    Yan Jin
    Ping-Li Sun
    Hyojin Kim
    Eunhyang Park
    Hyo Sup Shim
    Sanghoon Jheon
    Kwhanmien Kim
    Choon-Taek Lee
    Jin-Haeng Chung
    Virchows Archiv, 2015, 466 : 45 - 52
  • [36] Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis
    Masuda, Ken
    Fujiwara, Yutaka
    Shinno, Yuki
    Mizuno, Takaaki
    Sato, Jun
    Morita, Ryo
    Matsumoto, Yuji
    Murakami, Shuji
    Goto, Yasushi
    Kanda, Shintaro
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Ohe, Yuichiro
    JOURNAL OF THORACIC DISEASE, 2019, 11 (07) : 2965 - 2972
  • [37] An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.
    Mezquita, Laura
    Jovelet, Cecile
    Lacroix, Ludovic
    Planchard, David
    Recondo, Gonzalo
    Pailler, Emma
    Auclin, Edouard
    Plagnol, Vincent
    Howarth, Karen
    Morris, Clive D.
    Green, Emma
    Rouleau, Etienne
    Nicotra, Claudio
    Caramella, Caroline
    Adam, Julien
    Auger, Nathalie
    Farace, Francoise
    Friboulet, Luc
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations
    Solomon, B. J.
    Martini, J-F.
    Ou, S-H. I.
    Chiari, R.
    Soo, R. A.
    Bearz, A.
    Li, S.
    Thurm, H.
    Lin, C-C.
    Riely, G. J.
    Bauer, T. M.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2018, 29 : 495 - 495
  • [39] Screening for ROS1 fusions in patients with advanced non-small cell lung carcinomas using the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody
    Conde, Esther
    Hernandez, Susana
    Benito, Amparo
    Caminoa, Alejandra
    Garrido, Pilar
    Lopez-Rios, Fernando
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2021, 21 (05) : 437 - 444
  • [40] Clinical characteristics of patients with ROS1 gene rearrangement in non-small cell lung cancer: a meta-analysis
    Bi, Huanhuan
    Ren, Dunqiang
    Ding, Xiaoqian
    Yin, Xiaojiao
    Cui, Shichao
    Guo, Caihong
    Wang, Hongmei
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (07) : 4383 - +
12345